Inovative Treatment
Nanomed Targeting Systems Develops Innovative Treatment For Atrial Fibrillation (AF) And Post-Operative AF (POAF)
Company Overview
NanoMed Targeting Systems (NTS), is an early stage company founded in Oklahoma City, seeks to develop, manufacture and market targeted delivery systems for nanomedicines. Its platform technology delivers magnetic nanoformulations carrying therapeutic payload(s), targeted by a non-invasive proprietary magnetic guiding system. NTS is currently developing Targeting Systems to: (a) treat early AF, the most common cardiac arrhythmia worldwide, and (b) prevent POAF.
The Reason:
- AF is the most common cardiac arrhythmia, affecting 5 million Americans (15 million in the Western world), with more than 160,000 new cases diagnosed in the U.S. each year
- AF is such a significant healthcare problem in the U.S. that the Senate acknowledged the high costs to our nation and the 1:4 risk that those older than 40 will develop AF in their lifetime.
- RF Ablation – the leading treatment of AF – has higher risk and cost and about 50% of the patients need another procedure within 5 years.
- Post-Operative AF currently does not have a reliable prevention.
NanoMed AFIB Solution
NTS is presenting a novel alternative to ablation that recognizes the importance of the ganglionated plexi (GP) in the formation of AF: The procedure consists of an injectable solution containing very small magnetic particles (nanoparticles) carrying calcium that will be localized to the nerve clusters with abnormally high activity by a powerful external magnetic field. Once navigated to the targeted GP, these calcium will be released and inactivate the nerves, terminating the AF without the side effects associated with ablation procedures, such as damage to the working muscle of the heart. NTS expects that after its procedure, AF will be inhibited and the need for medication will be substantially diminished.
Contact Our Team
Fill out the contact form to get in touch with us. We are here to help and answer any questions you may have.